RESUMEN
BACKGROUND: Atrial fibrillation (AF) is well-known risk factor for cardiac embolic events, especially cerebrovascular events. The association between AF and lipid markers was evaluated. Among all these markers, lipoprotein(a), or (Lp(a), was also investigated. The aim of our study was to evaluate the characteristics of the lipid profile in patients with AF, focusing on Lp(a) levels. MATERIAL/METHODS: One hundred and one patients with AF were included in the study group. We used 101 patients without AF, matched by sex and age with the study group, as the control group. Total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, Lp(a), and the LDL/HDL, COL/LDL, and COL/HDL indexes were measured. The study was performed in Spain with a Caucasian population. RESULTS: Among all the variables included there was statistical difference only between groups in the COL/HDL index, showing a greater value in the group of patients with AF. No difference was found in Lp(a) levels between the groups. CONCLUSIONS: Although some studies have tried to show a possible relationship between AF and high Lp(a) levels, we found no such relationship in our study, although ethnic differences could explain, at least in part, these results in our patients when compared with other ethnic populations.
Asunto(s)
Fibrilación Atrial , Lípidos/sangre , Lipoproteína(a)/sangre , Anciano , Biomarcadores/sangre , Estudios de Casos y Controles , Colesterol/sangre , Colesterol/genética , HDL-Colesterol/sangre , HDL-Colesterol/genética , LDL-Colesterol/sangre , LDL-Colesterol/genética , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Lípidos/genética , Lipoproteína(a)/genética , Lipoproteínas LDL/sangre , Lipoproteínas LDL/genética , Masculino , Factores de Riesgo , Triglicéridos/sangre , Triglicéridos/genética , Población Blanca/genéticaRESUMEN
Lipoprotein (a) [Lp(a)] may produce thrombogenic effects by modulating the fibrinolytic system. Elevated levels of Lp(a) have also been associated with an increased risk for atherosclerosis. Because atherosclerosis is more prevalent among patients with end-stage renal disease, the role of Lp(a) among patients on hemodialysis is analyzed. Twenty patients were studied. Lp(a) was measured before and after a hemodialysis session and before the following session. Between the first and second measures there was no statistical difference but when first and third measures were compared, a statistical difference (increase) was found. In conclusion, changes in Lp(a) levels were found and perhaps these changes are related to the episodic inflammation affecting patients on hemodialysis. The significance of these changes and the role in accelerating atherosclerosis in patients with end-stage renal disease are unknown.